A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine

Abstract This study compared weight and cardiometabolic changes after short-term treatment of olanzapine/samidorphan and olanzapine. Eligible criteria for an included trial were ≤ 24 weeks, randomized controlled trials (RCTs) that compared olanzapine/samidorphan and olanzapine treatments in patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Manit Srisurapanont, Sirijit Suttajit, Surinporn Likhitsathian, Benchalak Maneeton, Narong Maneeton
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/717345612651402190bb409c7f0f98a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:717345612651402190bb409c7f0f98a2
record_format	dspace
spelling	oai:doaj.org-article:717345612651402190bb409c7f0f98a22021-12-02T18:15:33ZA meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine10.1038/s41598-021-87285-w2045-2322https://doaj.org/article/717345612651402190bb409c7f0f98a22021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87285-whttps://doaj.org/toc/2045-2322Abstract This study compared weight and cardiometabolic changes after short-term treatment of olanzapine/samidorphan and olanzapine. Eligible criteria for an included trial were ≤ 24 weeks, randomized controlled trials (RCTs) that compared olanzapine/samidorphan and olanzapine treatments in patients/healthy volunteers and reported weight or cardiometabolic outcomes. Three databases were searched on October 31, 2020. Primary outcomes included weight changes and all-cause dropout rates. Standardized mean differences (SMDs) and risk ratios (RRs) were computed and pooled using a random-effect model. This meta-analysis included four RCTs (n = 1195). The heterogeneous data revealed that weight changes were not significantly different between olanzapine/samidorphan and olanzapine groups (4 RCTs, SDM = − 0.19, 95% CI − 0.45 to 0.07, I 2 = 75%). The whole-sample, pooled RR of all-cause dropout rates (4 RCTs, RR = 1.02, 95% CI 0.84 to 1.23, I 2 = 0%) was not significant different between olanzapine/samidorphan and olanzapine groups. A lower percentage of males and a lower initial body mass index were associated with the greater effect of samidorphan in preventing olanzapine-induced weight gain. Current evidence is insufficient to support the use of samidorphan to prevent olanzapine-induced weight gain and olanzapine-induced cardiometabolic abnormalities. Samidorphan is well accepted by olanzapine-treated patients.Manit SrisurapanontSirijit SuttajitSurinporn LikhitsathianBenchalak ManeetonNarong ManeetonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Manit Srisurapanont Sirijit Suttajit Surinporn Likhitsathian Benchalak Maneeton Narong Maneeton A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
description	Abstract This study compared weight and cardiometabolic changes after short-term treatment of olanzapine/samidorphan and olanzapine. Eligible criteria for an included trial were ≤ 24 weeks, randomized controlled trials (RCTs) that compared olanzapine/samidorphan and olanzapine treatments in patients/healthy volunteers and reported weight or cardiometabolic outcomes. Three databases were searched on October 31, 2020. Primary outcomes included weight changes and all-cause dropout rates. Standardized mean differences (SMDs) and risk ratios (RRs) were computed and pooled using a random-effect model. This meta-analysis included four RCTs (n = 1195). The heterogeneous data revealed that weight changes were not significantly different between olanzapine/samidorphan and olanzapine groups (4 RCTs, SDM = − 0.19, 95% CI − 0.45 to 0.07, I 2 = 75%). The whole-sample, pooled RR of all-cause dropout rates (4 RCTs, RR = 1.02, 95% CI 0.84 to 1.23, I 2 = 0%) was not significant different between olanzapine/samidorphan and olanzapine groups. A lower percentage of males and a lower initial body mass index were associated with the greater effect of samidorphan in preventing olanzapine-induced weight gain. Current evidence is insufficient to support the use of samidorphan to prevent olanzapine-induced weight gain and olanzapine-induced cardiometabolic abnormalities. Samidorphan is well accepted by olanzapine-treated patients.
format	article
author	Manit Srisurapanont Sirijit Suttajit Surinporn Likhitsathian Benchalak Maneeton Narong Maneeton
author_facet	Manit Srisurapanont Sirijit Suttajit Surinporn Likhitsathian Benchalak Maneeton Narong Maneeton
author_sort	Manit Srisurapanont
title	A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
title_short	A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
title_full	A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
title_fullStr	A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
title_full_unstemmed	A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
title_sort	meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/717345612651402190bb409c7f0f98a2
work_keys_str_mv	AT manitsrisurapanont ametaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine AT sirijitsuttajit ametaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine AT surinpornlikhitsathian ametaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine AT benchalakmaneeton ametaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine AT narongmaneeton ametaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine AT manitsrisurapanont metaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine AT sirijitsuttajit metaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine AT surinpornlikhitsathian metaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine AT benchalakmaneeton metaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine AT narongmaneeton metaanalysiscomparingshorttermweightandcardiometabolicchangesbetweenolanzapinesamidorphanandolanzapine
_version_	1718378339004055552

A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine

Ejemplares similares